--- Chain 8 for Question 158 ---
Status: PRUNED
Is Active Flag: False
Finish Reason: worker_terminated_unexpectedly
Reasoning Complete Flag: True
Error: None
Prompt Tokens: 210
Completion Tokens: 1572
Completed Thoughts: 8
Accumulated Pruned Count: 2
Pruned at Analysis Step: 12
Pruned By Chain ID: q158_c6
Final Processed Boundaries: [0, 1379, 1686, 2607, 3612, 3826, 4090, 4594]

--- Full Content ---
Okay, let's try to figure this out. So, the question is about transcription factors and how mutations affect their function. Hmm, I'm a bit rusty, but I'll think it through.

So, the setup: there's a transcription factor subunit that's inactive until it gets a signal. The signal comes from a membrane phosphorylation cascade. When the Ser residues in the transactivation domain get phosphorylated, the subunit dimerizes, goes into the nucleus, and helps with gene transcription.

Now, there are two mutations mentioned. Mutation X is a missense in the transactivation domain and is recessive loss-of-function. That probably means that for the function to be lost, both alleles need to have the mutation. Because recessive mutations usually require two copies to show the phenotype.

Mutation Y is a heterozygous mutation in the dimerization domain and is dominant-negative. Dominant-negative means that even one copy of the mutated allele can interfere with the normal function of the protein. So, it's like the mutant version can't do its job, but it also messes up the normal allele.

The question is about the molecular phenotype when mutation Y is present.

Looking at the options:

Option A: Change of conformation and gain-of-function. Hmm, dominant-negative usually causes loss of function, not gain. So maybe not A.

Option B: Protein degradation and loss of wild-type. Wait, dominant-negative often leads to the proteins not working properly, maybe they form aggregates or can't function. But does the mutation Y cause the protein to be degraded? I'm not sure. Or does it interfere with the function without degrading?

Option C: Loss of dimerization and wild-type phenotype. Wait, but the mutation is in the dimerization domain, so that would affect dimerization. If the subunit can't dimerize, then it can't go into the nucleus. But the phenotype is wild-type? That doesn't make sense because if the dimerization is impaired, then the transcription factor can't work. So the phenotype would be loss of function, not wild-type.

Option D: Protein aggregation and loss of function. Aggregation sounds like the proteins might form insoluble clumps, which would prevent them from functioning. If Y is dominant-negative, the mutant subunits might interfere with the wild-type ones. So when the cell makes both wild-type and Y mutant proteins, the Y proteins might bind to wild-type, preventing them from dimerizing correctly. This could lead to the formation of aggregates (misfolded proteins sometimes aggregate), and the overall function would be lost. So the phenotype would be loss of function.

Wait, but thinking again: the mutation Y is in the dimerization domain. So when the transcription factor is trying to dimerize, the mutant subunit can't form the dimer correctly. So perhaps the mutant subunit can't dimerize with itself or with wild-type. If it's dominant-negative, the presence of Y would mean that any wild-type subunits can't form functional dimers because Y might bind to them and prevent proper dimer formation.

So the result would be that the transcription factor can't dimerize, so it stays in the cytoplasm and doesn't go into the nucleus. This would cause a loss of function, right?

But looking back at the options, option D says protein aggregation and loss. So, if the proteins can't dimerize properly, maybe they form aggregates because the dimerization is necessary for their proper folding or transport. Without proper folding, the proteins might aggregate.

Alternatively, another possibility is that the mutant Y doesn't allow the protein to be phosphorylated correctly. But wait, the phosphorylation happens in the transactivation domain, which is different from the dimerization domain. So mutation Y is in dimerization, so maybe whether it gets phosphorylated is a separate issue.

Wait, when the transactivation domain is phosphorylated, the protein changes conformation, allowing dimerization. Oh, but in this case, the mutation Y is in the dimerization domain, so even if the transactivation is phosphorylated, the dimerization can't happen.

Wait, but the question is about the presence of mutation Y. So the person is heterozygous for Y. So in their cells, half the transcription factors would have the Y mutation, and half would be wild-type.

So when the cell needs to activate the transcription factor, the phosphorylation occurs. The wild-type and mutant subunits get phosphorylated. But when they try to dimerize, the mutant subunit can't form a dimer correctly. So the mutant subunit could possibly interfere with the wild-type subunits.

Wait, the dominant-negative effect: perhaps the mutant Y can't form a dimer by itself, but when it's in a mixture with wild-type, the mutant Y might bind to the wild-type, preventing them from forming a functional dimer. So the wild-type can't form dimers because the mutant is binding to them but not allowing proper dimerization.

So the result is that the transcription factors can't dimerize, so they don't go into the nucleus, and thus gene transcription doesn't happen. So the phenotype would be a loss of function.

Looking back at the options, option D is protein aggregation and loss. But why would aggregation occur? Because if the proteins can't dimerize, perhaps they misfold and aggregate. Or maybe the dominant-negative effect causes the mutant proteins to form non-functional aggregates, which then prevent the wild-type from functioning.

Alternatively, mutation Y is dominant-negative and causes the proteins to be unable to function, but maybe not necessarily aggregate. So maybe the main issue is that dimerization doesn't happen, leading to loss of function. But the options don't directly have that.

Looking at the options again:

Option B says protein degradation and loss of wild-type function. But I'm not sure if protein degradation is a direct result of the dominant-negative mutation Y.

Option D: protein aggregation and loss of function. That could make sense if the mutant proteins cause the wild-type ones to aggregate or if the mutant proteins themselves aggregate.

Wait, but I think I read before that dominant-negative mutations can cause the proteins to misfold and aggregate. So if the mutant Y can't form a proper dimer, when mixed with wild-type, they might form some sort of aggregates or inclusion bodies, which would prevent the wild-type from functioning.

So, in that case, the phenotype would be loss of function due to aggregation and the inability to form functional dimers.

So the correct answer would be D: protein aggregation and loss of function.


The question involves a transcription factor subunit that becomes active upon phosphorylation in the transactivation domain, allowing it to dimerize, enter the nucleus, and facilitate gene transcription. Two mutations are described: a recessive loss-of-function mutation (X) in the transactivation domain and a dominant-negative mutation (Y) in the dimerization domain. The task is to determine the molecular phenotype caused by mutation Y.

Mutation Y is heterozygous and dominant-negative, meaning that even one copy of the mutant allele can interfere with the function of the protein. Since Y is located in the dimerization domain, it likely disrupts the ability of the transcription factor subunits to form functional dimers. This disruption prevents the transcription factor from entering the nucleus and participating in gene transcription, leading to a loss of function.

Dominant-negative mutations often result in misfolded or aggregated proteins. In this case, the mutant Y subunits may bind to wild-type subunits, preventing proper dimerization and potentially causing the formation